• Urothelial Bladder Cancer — Year in Review Series on Relevant New Datasets and Advances
    Jun 25 2026

    Featuring perspectives from Dr Ashish M Kamat and Prof Thomas Powles, including the following topics:

    • Introduction: Life After Radical Cystectomy (0:00)
    • Muscle-Invasive Bladder Cancer — Prof Powles (9:15)
    • Non-Muscle-Invasive Bladder Cancer — Dr Kamat (37:49)

    CME information and select publications

    Show More Show Less
    58 mins
  • Prostate Cancer — Fifth Annual National General Medical Oncology Summit
    Jun 23 2026

    Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics:

    • Introduction (0:00)
    • Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41)
    • Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16)

    CME information and select publications

    Show More Show Less
    50 mins
  • Urothelial Bladder Cancer — Fifth Annual National General Medical Oncology Summit
    Jun 17 2026

    Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:

    • Introduction (0:00)
    • Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)
    • Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)

    CME information and select publications

    Show More Show Less
    49 mins
  • Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting
    Jun 16 2026

    Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics:

    • Introduction (0:00)
    • Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12)
    • Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54)
    • Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49)
    • Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12)
    • Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26)

    CME information and select publications

    Show More Show Less
    1 hr and 58 mins
  • Localized Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting
    Jun 12 2026

    Dr Thomas Hutson from the Sarah Cannon Research Institute in Abilene, Texas, Dr Eric A Singer from The Ohio State University Comprehensive Cancer Center in Columbus and Dr Ulka Vaishampayan from the University of Michigan Health Rogel Cancer Center in Ann Arbor discuss recent data surrounding the management of localized renal cell carcinoma and share their perspectives on the clinical application.

    CME information and select publications

    Show More Show Less
    1 hr and 29 mins
  • Genitourinary Cancers — 5-Minute Journal Club Issue 2 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
    Jun 5 2026

    Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer.

    CME information and select publications

    Show More Show Less
    23 mins
  • Genitourinary Cancers — 5-Minute Journal Club Issue 1 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
    May 26 2026

    Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer.

    CME information and select publications here.

    Show More Show Less
    30 mins
  • PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida
    May 15 2026

    Dr Wassim Abida from Memorial Sloan Kettering Cancer Center in New York, New York, discusses the role of PARP inhibitors in the management of hormone-sensitive and castration-resistant metastatic prostate cancer.

    CME information and select publications here.

    Show More Show Less
    52 mins